Objectives: To review the literature on the cost-effectiveness of dengue vaccination in Southeast Asian countries and possibly to provide recommendations on promoting dengue vaccination in this region. Methods: A systematic search was conducted to identify relevant articles in 3 major databases (ProQuest, American Society of Tropical Medicine and Hygiene, and PubMed). Complete economic evaluation studies, including willingness-to-pay (WTP) studies, that were conducted in any Southeast Asian country were included in this study. Systematic review, nonefull-text, and non-English studies were specifically excluded. Results: Nine selected studies highlighted the economic evaluation of dengue vaccination in Southeast Asian countries by considering many parameters (eg, vaccine cost, vaccine efficacy, cost-effectiveness threshold, economic assessment, public acceptance, and WTP). All studies confirmed that dengue vaccine can be used as a prevention strategy to reduce the incidence rate of dengue cases by providing a variance of high cost-effectiveness values. In addition, communities provided a good assessment, acceptance, and WTP value for the vaccine. Conclusions: The use of dengue vaccine could reduce the burden of disease and economic burden due to dengue infection in Southeast Asian countries. The efficacy of dengue vaccine was estimated to be 50-95% for those <9 years, 9 years, and >9 years. In particular, several studies reported that dengue vaccine could be categorized as a cost-effective intervention in Southeast Asian countries within certain conditions.
Introduction
Over the last decade, dengue fever has been reported to be the most prevalent arboviral fever worldwide, with up to 40% of the world's population living in endemic regions and at risk for dengue infection. 1 The dengue virus, which is transmitted through mosquitoes, has been causing serious problems in several tropical countries. 2 It has been reported that during the period 2001 to 2010, the number of dengue cases in Southeast Asian countries was 2.9 million, with 5906 deaths. 3 Dengue infections were also related to 1.8 billion cases in Southeast Asian and Western Pacific countries. 4, 5 Southeast Asia is one of the regions in the world with a relatively high incidence rate of dengue infection and a short epidemic cycle of 3 to 5 years. Several studies reported that dengue fever in Southeast Asian countries was responsible for 75% of the total disease and economic burden due to dengue fever in the world. 4, 6, 7 In particular, an annual economic burden due to dengue infection in Southeast Asian countries was estimated to be $950 million ($1.65 per capita). 3 Several prevention strategies (eg, surveillance, vector control, and community-based disease prevention) that have been implemented in these countries could not be categorized as cost-effective interventions. 8 A national surveillance system, which was conducted to determine the incidence rates in the context of prevention efforts, could not significantly reduce the number of dengue infections. 9 Nevertheless, controlling the vector of mosquitoes or larvae remains ineffective, 10 which might be caused by the lack of support from the community in comprehensive prevention strategies. 11 Even though several prevention strategies have been implemented in Southeast Asian countries, most countries in this region are still facing a continuous rise in the number of dengue cases. 12, 13 Till now, governments are seeking the most effective strategies to control dengue disease transmission. 14 In the context of giving examples on the situation of dengue prevention strategies in other regions, dengue vaccination has been confirmed to be the most cost-effective strategy in reducing the number of dengue cases, specifically in countries with a high number of cases and extensive vaccination coverage. 15 Many studies on dengue vaccine, including the specific vaccine type, mode of action, immune response, and vaccine effectiveness, confirmed promising results in reducing the number of dengue infection cases. 16e18 A preliminary clinical trial study, which took into account the correlation between the vaccine use with its impact on reducing the disease severity and viral transmission, confirmed a significant number of prevented infection cases. 17 A phase III clinical trial study in a group of 9-to 16- year-old volunteers to be analyzed over a period of 25 months indicated that vaccination could reduce dengue fever (all serotypes) in most (2 out of 3) of the volunteers and reduce the length of stay. 18 In particular, a previous study confirmed that dengue vaccination in Southeast Asian countries could save medical expenses of up to $17 and highlighted that vaccination was more cost-effective than vector control strategy. 19 Another study also reported that a vaccination program could reduce 24% of dengue hemorrhagic fever cases. 20 In particular, a previous study in 10 endemic countries confirmed that dengue vaccination could be highly cost-effective and a cost-effective intervention in 3 and 7 countries, respectively, according to their gross domestic product (GDP) per-capita values. 21 Despite the fact that dengue vaccine has been licensed in several Asian countries and has proven its cost-effectiveness, a postlicensing monitoring and evaluation (eg, monitoring and registration systems for immunization, reporting, and long-term safety assessments) is still required to be implemented. 22 Considering the results from previous studies, it can be summarized that dengue vaccine in many cases has an ability to reduce the transmission of dengue infection in the community. 23 Furthermore, the World Health Organization has confirmed the potential benefits of dengue vaccine to be implemented into the national routine immunization program in countries with high endemicity level as an effort to control dengue infection. 24e26 Nevertheless, before the introduction of dengue vaccine, economic evaluation studies should be conducted to analyze the cost-effectiveness of the vaccination program in a specific country or region, such as in Southeast Asia, which has been highlighted as one of the regions with the highest prevalence of dengue infection in the world. 27e29 The objective of this study was to systematically review all published studies on economic evaluations of dengue vaccination in Southeast Asian countries and to conduct a comprehensive policy recommendation on introducing dengue vaccine in this region.
Methods

Search Strategy
Two of the investigators (W.S. and A.A.S.) searched 3 databases (ProQuest, American Society of Tropical Medicine and Hygiene [ASTMH], and PubMed) for all published studies on economic evaluations of dengue vaccination, including willingness-to-pay (WTP) studies, in Southeast Asian countries. The search used the following keywords: "economic evaluation" OR "cost minimization" OR" "cost-effectiveness" OR "cost utility" OR "cost benefit" OR "willingness-to-pay" AND "dengue" OR "dengue fever" OR "dengue hemorrhagic fever" AND "vaccine" OR "vaccination" OR "immunization."
Inclusion and Exclusion Criteria
All complete economic evaluation studies in English that were conducted in any Southeast Asian country according to the Association of Southeast Asian Nations and published in the period 2000 to 2017 were included in this study. Nevertheless, systematic review studies and studies available in abstracts only were excluded. From the selected studies, we extracted both qualitative and quantitative data on design study, information about vaccine, cost component, outcome measurement, and results. The required criteria of each included article are presented in Table 1 .
In particular, economic results from the analyses were converted into 2016 international dollars by using purchasing power parities and deflators as measured by the annual growth rate in the country-specific GDP implicit deflator. 30 In case a study did not specify the year of cost, we assumed the year of cost to be the same as the year of publication.
Results
Literature Search
The literature search identified 162, 60, and 33 original articles in PubMed, ProQuest, and ASTMH, respectively. We selected 9, 2, and 2 articles after excluding 153, 58, and 31 articles in PubMed, Pro-Quest, and ASTMH, respectively, because these were pharmacological and epidemiological studies. From these 13 articles, we further excluded 4 duplicate articles. In total, there were 9 studies for final review, as presented in Figure 1 .
Our 9 selected studies were from 7 different countries: Indonesia (n ¼ 3), Singapore (n ¼ 1), Thailand (n ¼ 1), Philippines (n ¼ 1), Vietnam-Thailand (n ¼ 1), Malaysia (n ¼ 1), and Southeast Asia (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam; n ¼ 1). 19,31e38 The oldest article that appeared from our search was from 2004, focusing on the cost-effectiveness of a pediatric dengue vaccine in 10 countries in Southeast Asia (ie, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam), 30 and the most recent one was an article from 2017 addressing the costeffectiveness of dengue vaccine in Malaysia. 38 The most relevant aspects of these studies are presented in Table 2 . 
Assessing Economic Evaluation Studies
Study design and data collection
All selected studies, which have been conducted in specific targeted populations (eg, household, society, and public and private hospitals), provided information on the economic analysis, the acceptance, and the WTP value of the society related to the implementation of dengue vaccination in Southeast Asian countries. In particular, 4 studies applied cost-effectiveness analysis (CEA) 19, 31, 33, 38 and other studies specifically estimated the public acceptance and the WTP value of vaccine. 34e37 The CEA studies provided the incremental cost-effectiveness ratio (ICER) by comparing a scenario of vaccination with that of no vaccination, so that the difference amount of the cost and outcome for vaccination to be implemented could be estimated. 39 Other studies considered the public acceptance and the WTP value of vaccine as the outcome parameters by taking the monetary unit into account. 39 A study on cost-effectiveness of a pediatric dengue vaccine in 10 countries, which was conducted by Shepard et al, 19 applied a standard approach to estimating cost-effectiveness values by comparing 2 scenarios (with vaccination and without vaccination), evaluating costs and benefits in each scenario, considering cost per disability-adjusted life-year (DALY) saved, and taking vector control programs into account. A study by Carrasco et al 31 specifically calculated direct and indirect costs of hospitalized and ambulatory cases due to dengue in Singapore. Data related to indirect cost on both cases were collected by using the human-capital and friction cost methods. Two studies in Thailand and the Philippines calculated ICERs in the context of cost per DALY averted, compared with no dengue vaccination. 32, 33 A study by Shafie et al 38 in 2017 evaluated the cost-effectiveness and impact of dengue vaccination in Malaysia by using a dynamic transmission mathematical model. A multicountry study, which focused on the household WTP for dengue vaccination in Vietnam and Thailand, collected the median value of WTP by assuming that 50% of the population would purchase vaccine. 34 Three previous studies in Indonesia collected parametric estimates of WTP, which are sensitive to the choice of distribution and functional forms of household demand. In particular, demographic information of participants was collected to measure the level of knowledge, attitude, and practice related to dengue vaccine and other prevention strategies. 35e40 More information about study design and data collection of selected studies is presented in Table 3 .
Study perspective, time horizon, discount rate, and use of mathematical modeling
The choice of perspective in economic evaluation studies is critical because it determines the cost component that must be included in the study. 39 All the CEA studies applied societal, provider, and healthcare perspectives. 19, 31, 33, 38 Individual perspective was applied only in those studies that focused on the public acceptance and the WTP of vaccine. 31 (1) and Indonesia (3) 2 retrieved studies = Thailand (1) and Philippines (1) 2 retrieved studies = Southeast Asia (1) and Indonesia (1) 4 arƟcles were idenƟfied as duplicated arƟcles 9 included studies to be reviewed in this study 38 The potential cost-effectiveness of different dengue vaccination programs in Malaysia: a valuebased pricing assessment using dynamic transmission mathematical modeling
Malaysia
To evaluate the cost-effectiveness and impact of dengue vaccination in Malaysia from both provider and societal perspectives by using a dynamic transmission mathematical model
Cost-effectiveness analysis 1. Malaysian-specific data, evidence from the latest phase III studies, a collection data of long-term safety, and efficacy were collected 2. Age-structured deterministic compartment, vector-host, and serotype-specific deterministic compartment models were built to identify the optimal age of vaccination and routine vaccination strategies and/or mass catch-up vaccination strategies 3. A value-based pricing was applied as the cost-effective threshold price instead of ICER DALY indicates disability-adjusted life-year; DF, dengue fever; DHF, dengue hemorrhagic fever; DSS, dengue shock syndrome; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; WTP, willingness to pay. The interpretation of results in economic evaluation studies is associated with the application of time horizon. The calculation of benefit-to-cost ratio in a long-term intervention, such as vaccination, should consider a long time horizon (>1 year). Five selected CEA studies applied 5 different time horizons: 1 year, 20 years, 65 years, 71 years, and 5 to 30 years, 19,31e33,38 whereas other studies did not take this into account. When a study applies a time horizon of more than 1 year, the health effect and cost should be adjusted with a discounting rate. Four selected CEA studies applied 4 specific discount rates: 3%, 6%, 15%, and 18%. 19,31e33,38 Other studies did not apply a discount rate (see Table 3 ).
From all the selected studies, only 3 studies took mathematical modeling into account. 32, 33, 38 A study by Lee et al 32 developed a decision-analytic Markov simulation model to estimate the costeffectiveness value of implementing a dengue vaccine to a population of 1-year-olds or younger in Thailand from a societal perspective. 32 In addition, a study in the Philippines by Shim 33 developed an age-structured model of dengue transmission and vaccination by comparing 2 vaccination scenarios entailing routine vaccination programs both with and without catch-up vaccination. Shafie et al 38 applied a dynamic transmission mathematical model to evaluate the cost-effectiveness and impact of dengue vaccination in Malaysia. More detailed information is presented in Table 3 .
Sensitivity analysis
Because economic evaluation studies should consider the uncertainty aspect of various used parameters, it seems critical to analyze the impact of these uncertain parameters by conducting a sensitivity analysis. In this study, only 5 selected studies conducted sensitivity analyses by considering various parameters, such as vaccine price, use of other vaccines, dengue diagnoses and symptoms, duration of illness, degree of dengue fever, estimated costs of illness, threshold values, vaccine mechanisms, and impacts on decreased transmission rates or dengue spread. 19,31e33 Differing with other studies, Shafie et al 38 considered more parameters in the sensitivity analyses, such as geographical Vaccination was estimated to be 95% efficacious in providing lifetime protection against each dengue virus serotypes and 0.25% reduction in recipients' annual risk of infection Carrasco et al 31 2-and 3-dose vaccine 10 y 75% Vaccine efficacy was estimated to be 80%, which was relatively low (compared with that in previous studies) Lee et al 32 3-dose vaccine 10-30 y NR Vaccine efficacy varied in a range of 50%-95% Shim 33 2 strategies: A (given to 9-yold children) and B (given to 9-to 15-y-old children, and 9-y-old children through catch-up and routine program) NR NR Vaccine efficacy was estimated to be 61.1%, 79.2%, and 90.9% against infection among seronegative group of !9 y old, seropositive group of !9 y old, and against DHF among seropositive group of !9 y old, respectively Lee et al 34 3 37 NR NR NR NR Shafie et al 38 3-dose vaccine at schoolbased (9-17 y old) and community-based age (18-30 y old); routine and catch-up strategies were taken into account 10 y 20%-80% and 90%-100% (including coverage for catch-up cohort in several strategies)
Vaccine efficacy was estimated to be 55.7%-64.5% according to pooled phase III efficacy data; relative efficacy against infection was estimated in a range of 0%-100% for ambulatory cases DHF indicates dengue hemorrhagic fever; NR, not reported; SEAR, Southeast Asian Region. 
Vaccine information
Most of the studies (n ¼ 5) focused on the use of a 3-dose vaccine 19 ,31e34 and 2 of them made a further comparison between the use of 3-dose and 2-dose vaccines. 37, 39 Targeted age groups varied from the ages of 6, 12, and 18 months to younger than 9, 9, and older than 9 years. 19,31e34,38 The protective duration of vaccine was estimated to be 10 years 19, 31, 38 and 10 to 30 years, 32, 33 whereas the coverage of vaccination was estimated to be 20% to 80%, 70%, 75%, and 90% to 100%. 19, 31, 38 Regarding vaccine efficacy, several studies estimated the values to be 50%, 55.7% to 64.5%, 70%, 80%, and 95%. 19, 32, 34, 38 Only 1 study specifically estimated the vaccine efficacy on the basis of age: younger than 9 years (61.6%), 9 years (79.2%), and older than 9 years (90.9%). 33 All information about vaccine is presented in Table 4 .
Cost estimation
Costs or opportunity costs are defined as the value of lost opportunities as a result of resource use in an activity. 39 In economic evaluation studies, cost appears to be an important aspect to be estimated because of its limited resources in many countries, including Southeast Asian countries. All studies estimated the vaccination cost. 19,31e38 Four studies calculated direct and indirect costs because they applied a societal perspective. 19,31e33,38 In particular, 2 studies took disability weights into account 32, 33 and only 1 study considered the cost of minor side effects due to vaccination (see Table 5 ). 32 
Primary results
All studies considered vaccine price and administration cost to estimate total vaccination cost. Shepard et al 19 applied vaccine prices of $0.50 and $10.00 for the public and private sectors, respectively. Carrasco et al 31 considered vaccine prices of $58.90 (3 doses with 10 years of immunity) and $319.00 (2 long-lived immune doses). 31 A range of $0.12 to $65.70 (total for 3 doses) was applied in Thailand. 32 Lee et al 34 considered vaccine prices at a range of $0.0004 to $0.04 and $0.16 to $39.34 in Vietnam and Thailand, respectively. 34 A WTP study in Indonesia applied vaccine prices of $0.0002 to $0.004. 35, 36 Administration cost varied from $0.50 to $6.00 (see Table 6 ). 19 Shepard et al 19 confirmed that the incremental cost of vaccinating 1 child against dengue would be $4.85/DALY and $39.10/ DALY in the public and private sectors, respectively. 19 In particular, a study in Singapore mentioned that the thresholds for vaccination to be cost-effective in Singapore would range from $105.70 to $546.30 per dose. 31 A study in Thailand showed that vaccination would be a highly cost-effective intervention (ICER < 4289) for all scenarios under certain conditions, such as a point of vaccine price at $4.93, a dominated vaccine efficacy of at least 75%, and an administration cost of a 3-dose vaccine at $0.12 or less. 32 A study in the Philippines confirmed that dengue vaccination would be cost-effective at a WTP value of $0.15 per qualityadjusted life-year (QALY) in 69% of the model iterations. This likelihood of cost-effectiveness would increase up to 74% within an acceptability threshold of $0.46/QALY. 33 Lee et al 34 highlighted that the WTP values of vaccine were $0.004 ($0.002 per dose) and $5.56 ($1.85 per dose) in Vietnam and Thailand, respectively. 34 Hadisoemarto and Castro 35 observed that distribution of maximum WTP in Indonesia was achieved when 37.2% of participants expressed their WTP to be below $0.0003. Another study by Harapan et al 36 reported that the mean and median values of WTP on dengue vaccine were $0.001 (95% confidence interval [CI] 3.86-4.23) and $0.001 (95% CI 3.74-4.23), respectively. 36 In addition, Shafie et al 38 confirmed that the best vaccination strategy to be implemented in Malaysia was a routine vaccination program for the age of 13 years, coupled with a catch-up program for the age of 14 to 30 years. The total price per dose values of $50 491 to $95 372 and $23 843 to $44 180 were likely to be cost-effective and highly cost-effective thresholds, respectively, from the provider perspective. The highly cost-effective threshold could even be $21 038 to $24 544 by assuming no underreporting cases in Malaysia (see Table 6 ). 38 
Discussion
Dengue vaccination is considered to be one of the most costeffective interventions to prevent the spread of dengue fever in many countries within certain conditions. Nevertheless, more scientific evidences regarding its potential benefits are still required because the number of its economic evaluation studies and the use of vaccine itself are still very limited. Economic evaluation studies that have been conducted in several countries applied a modeling approach to predict the economic impact of vaccination by considering several alternative scenarios. 40, 41 Nevertheless, the implementation of modeling studies on the cost-effectiveness of dengue vaccine appears to be crucial before the introduction of dengue vaccine itself in each specific country. Most of the studies in this area applied a Markov simulation model and dynamic transmission model, which took herd immunity into account. 32, 38, 42 The models differed in assumptions and parameters related to the natural history and ecology of dengue in both humans and mosquitoes. 24 All included studies targeted a population group that had a relatively high risk of dengue infection in all settings (hospitals, communities, or households), which can be extrapolated into the general population. Several perspectives (eg, societal, individual, provider, payer, and healthcare perspectives) were applied to estimate the cost of illness due to dengue infection. Nevertheless, the determination of perspective was based on the research 32 Costs of vaccination, clinical visit, hospital visit, vaccine minor side effect, and disability weight Shim 33 Direct medical costs for healthcare perspective and direct and indirect costs for societal perspective Lee et al 34 Vaccination The best vaccination strategy to be implemented in Malaysia was program 1, which considered a routine vaccination program for the age group of 13 y, coupled with continued on next page question. In particular, cost-effectiveness values were calculated by comparing the use of vaccine with a situation of no vaccine and other scenarios (eg, vector control) to determine the best scenario or strategy in terms of cost-effectiveness values (cost/DALY or cost/QALY). Regarding the sensitivity analysis, several studies considered the mean burden of disease, total cost, and benefitcost ratio of the vaccination program, parameters related to the lifetime immune system and duration of dengue symptoms, and discount rate. Several studies reported the values of vaccine efficacy to be 50%, 70%, 80%, and 95%. 19, 31, 32, 34 A study by Shim 33 specifically mentioned values of vaccine efficacy in different age groups (<9 years: 61.6%; 9 years: 79.2%; and >9 years: 90.9%). These findings, however, are correlated with the fact that vaccination could reduce the mortality, morbidity, and disease burden by 82%. 19 A previous study also reported that a potential dengue vaccine has an ability to reduce the burden of dengue disease in moderate and high endemicity areas, 24 with a rate of efficacy for symptomatic dengue during the first 25 months being 60.3% (95% CI 55.7-64.5). 43 It has also proven to be able to reduce dengue fever in 4 serotypes (by 2/3 of the total volunteers), to prevent dengue cases (from 9 dengue cases), and to reduce the length of stay (8 out of 10 cases of dengue). 18 The efficacy of the vaccine on the specific serotype was reported to be 50.3%, 42.3%, 74.0%, and 77.7% for serotypes 1, 2, 3, and 4, respectively. Furthermore, a 3-dose regimen of CYD-TDV has been confirmed to have a good safety profile in a group of 2-to 11-year-olds with a history of yellow fever vaccination and elicited robust antibody responses that were balanced against the 4 serotypes. 44 The safety and immunogenicity of CYD-TDV have also been demonstrated through independent phase I trials in the United States and Colombia, 45 which confirmed that the safety profile of the CYD-TDV vaccine was similar to that of the placebo, with no marked difference in rates of adverse events. 46 The risk in seronegative vaccine recipients was higher than in seronegative controls, and the risk of severe virologically confirmed dengue in seropositive vaccine recipients was also lower than in seropositive controls. 47 In particular, pain at the injection site, itching, and mild erythema were the most common side effects that could be found in all age groups. 48 Even though dengue vaccine has the potential to reduce the burden of dengue disease, specifically in moderate and high endemicity areas, it has not yet been included in existing immunization programs in many countries. 24 Because an economic evaluation study is required by the government or insurance companies as a consideration on decision-making process, it should be comprehensively conducted to enable policy makers to make decisions more precisely while allocating resource and budget because in some countries, such as in Southeast Asian countries, dengue vaccination might be heavily subsidized by the government and would have an impact on healthcare policies. 49 The results on CEA of dengue vaccine in this study demonstrated that dengue vaccine can be considered as a cost-effective intervention, which might be developed and implemented in all regions. 50 It has been highlighted that the total cost of using dengue vaccine in Southeast Asia would be approximately $81.7 million annually, which could save $72.7 million compared with conventional treatment. Furthermore, about 1 million cost-effectiveness ratio of dengue vaccination would save 20 000 DALYs. The least costly or unfavorable cost-effectiveness ratio would be $683/DALY and the cost-effectiveness ratio with low vaccine efficacy would be $788 to $960/DALY, which were still lower than GDP per capita in Southeast Asian countries ($1083). 19 In particular, because vaccination is considered to be a long-term investment with high initial costs, the best vaccination strategy should be considered by the stakeholder. A study in Malaysia highlighted the potential of a routine vaccination program for the age of 13 years that was coupled with a catch-up program for the age of 14 to 30 years, which could be considered as the best vaccination strategy in the context of morbidity and mortality averted. 38 Despite the fact that this study has several limitations, such as the high heterogeneity among the included studies, and its inability to take into account the prevalence rate in the search strategy and the cost of overcoming side effects because of its relatively low cost, policy makers in Southeast Asian countries can consider this study to review evidence from all published studies on economic evaluations of dengue vaccination in Southeast Asian countries so as to conduct a comprehensive policy recommendation on introducing dengue vaccine in this region. Nevertheless, dengue vaccination has been proven to be a cost-effective intervention in several prioritized countries within certain age groups. 26 In a country with a relatively high burden of dengue infection, vaccination appears to be a very promising intervention. Yet, vaccine price is considered to be the most influential parameter in the cost-effectiveness value. 51e53 This situation should be highlighted by policy makers in Southeast Asian countries so that dengue vaccination can be sustainably implemented in this region.
Conclusions
The implementation of dengue vaccination could reduce the burden of disease and economic burden due to dengue infection in Southeast Asian countries. The efficacy of dengue vaccine was estimated to be 50% to 95% for those younger than 9 years, 9 years, and older than 9 years. In particular, several studies reported that dengue vaccination could be categorized as a cost-effective intervention in Southeast Asian countries within certain conditions.
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